Neurodegenerative disorders and nanoformulated drug development

Ari Nowacek, Lisa M. Kosloski, Howard Eliot Gendelman

Research output: Contribution to journalReview article

47 Citations (Scopus)

Abstract

Degenerative and inflammatory diseases of the CNS include, but are not limited to, Alzheimer's and Parkinson's disease, amyotrophic lateral sclerosis, stroke, multiple sclerosis and HIV-1-associated neurocognitive disorders. These are common, debilitating and, unfortunately, hold few therapeutic options. In recent years, the application of nanotechnologies as commonly used or developing medicines has served to improve pharmacokinetics and drug delivery specifically to CNS-diseased areas. In addition, nanomedical advances are leading to therapies that target CNS pathobiology and as such, can interrupt disordered protein aggregation, deliver functional neuroprotective proteins and alter the oxidant state of affected neural tissues. This article focuses on the pathobiology of common neurodegenerative disorders with a view towards how nanomedicine may be used to improve the clinical course of neurodegenerative disorders.

Original languageEnglish (US)
Pages (from-to)541-555
Number of pages15
JournalNanomedicine
Volume4
Issue number5
DOIs
StatePublished - Aug 12 2009

Fingerprint

drug development
Central Nervous System Diseases
Neurodegenerative Diseases
Nanomedicine
drug
Disease
Proteins
Medical nanotechnology
multiple sclerosis
Nanotechnology
protein
Pharmacokinetics
nanotechnology
Amyotrophic Lateral Sclerosis
human immunodeficiency virus
stroke
Drug delivery
Oxidants
oxidant
aggregation

Keywords

  • Alzheimer's disease
  • Amyotrophic lateral sclerosis
  • Fullerene
  • Nanomedicine
  • Nanoparticles
  • Neurodegeneration
  • Neuroregeneration
  • Parkinson's disease
  • Stroke

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Biomedical Engineering
  • Materials Science(all)

Cite this

Neurodegenerative disorders and nanoformulated drug development. / Nowacek, Ari; Kosloski, Lisa M.; Gendelman, Howard Eliot.

In: Nanomedicine, Vol. 4, No. 5, 12.08.2009, p. 541-555.

Research output: Contribution to journalReview article

Nowacek, Ari ; Kosloski, Lisa M. ; Gendelman, Howard Eliot. / Neurodegenerative disorders and nanoformulated drug development. In: Nanomedicine. 2009 ; Vol. 4, No. 5. pp. 541-555.
@article{826ce03eee5f4efea4c40cdc5f4d0580,
title = "Neurodegenerative disorders and nanoformulated drug development",
abstract = "Degenerative and inflammatory diseases of the CNS include, but are not limited to, Alzheimer's and Parkinson's disease, amyotrophic lateral sclerosis, stroke, multiple sclerosis and HIV-1-associated neurocognitive disorders. These are common, debilitating and, unfortunately, hold few therapeutic options. In recent years, the application of nanotechnologies as commonly used or developing medicines has served to improve pharmacokinetics and drug delivery specifically to CNS-diseased areas. In addition, nanomedical advances are leading to therapies that target CNS pathobiology and as such, can interrupt disordered protein aggregation, deliver functional neuroprotective proteins and alter the oxidant state of affected neural tissues. This article focuses on the pathobiology of common neurodegenerative disorders with a view towards how nanomedicine may be used to improve the clinical course of neurodegenerative disorders.",
keywords = "Alzheimer's disease, Amyotrophic lateral sclerosis, Fullerene, Nanomedicine, Nanoparticles, Neurodegeneration, Neuroregeneration, Parkinson's disease, Stroke",
author = "Ari Nowacek and Kosloski, {Lisa M.} and Gendelman, {Howard Eliot}",
year = "2009",
month = "8",
day = "12",
doi = "10.2217/nnm.09.37",
language = "English (US)",
volume = "4",
pages = "541--555",
journal = "Nanomedicine",
issn = "1743-5889",
publisher = "Future Medicine Ltd.",
number = "5",

}

TY - JOUR

T1 - Neurodegenerative disorders and nanoformulated drug development

AU - Nowacek, Ari

AU - Kosloski, Lisa M.

AU - Gendelman, Howard Eliot

PY - 2009/8/12

Y1 - 2009/8/12

N2 - Degenerative and inflammatory diseases of the CNS include, but are not limited to, Alzheimer's and Parkinson's disease, amyotrophic lateral sclerosis, stroke, multiple sclerosis and HIV-1-associated neurocognitive disorders. These are common, debilitating and, unfortunately, hold few therapeutic options. In recent years, the application of nanotechnologies as commonly used or developing medicines has served to improve pharmacokinetics and drug delivery specifically to CNS-diseased areas. In addition, nanomedical advances are leading to therapies that target CNS pathobiology and as such, can interrupt disordered protein aggregation, deliver functional neuroprotective proteins and alter the oxidant state of affected neural tissues. This article focuses on the pathobiology of common neurodegenerative disorders with a view towards how nanomedicine may be used to improve the clinical course of neurodegenerative disorders.

AB - Degenerative and inflammatory diseases of the CNS include, but are not limited to, Alzheimer's and Parkinson's disease, amyotrophic lateral sclerosis, stroke, multiple sclerosis and HIV-1-associated neurocognitive disorders. These are common, debilitating and, unfortunately, hold few therapeutic options. In recent years, the application of nanotechnologies as commonly used or developing medicines has served to improve pharmacokinetics and drug delivery specifically to CNS-diseased areas. In addition, nanomedical advances are leading to therapies that target CNS pathobiology and as such, can interrupt disordered protein aggregation, deliver functional neuroprotective proteins and alter the oxidant state of affected neural tissues. This article focuses on the pathobiology of common neurodegenerative disorders with a view towards how nanomedicine may be used to improve the clinical course of neurodegenerative disorders.

KW - Alzheimer's disease

KW - Amyotrophic lateral sclerosis

KW - Fullerene

KW - Nanomedicine

KW - Nanoparticles

KW - Neurodegeneration

KW - Neuroregeneration

KW - Parkinson's disease

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=68249158658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68249158658&partnerID=8YFLogxK

U2 - 10.2217/nnm.09.37

DO - 10.2217/nnm.09.37

M3 - Review article

C2 - 19572820

AN - SCOPUS:68249158658

VL - 4

SP - 541

EP - 555

JO - Nanomedicine

JF - Nanomedicine

SN - 1743-5889

IS - 5

ER -